Amgen Stock Surges 43.5% in Six Months on Strong Sales Growth
Nov 16, 2026 | By Kuldeep Jangid

Amgen shares gained 43.5% between May 15 and November 13, 2026, compared with a 2.6% rise in the S&P 500. In the six months before May 15, the stock had fallen by around 1%.
SUMMARY
- Amgen shares rose 43.5% in six months.
- Strong medicine sales boosted its growth.
- Amgen develops medicines for serious diseases.
The companys growth plans started showing results after key developments. The FDA approved UPLIZNA on December 11, 2025. Later on March 28, 2026, Amgen reported that Repatha reduced the risk of a first major cardiovascular event by 31% in high-risk patients.
In the third quarter of fiscal 2026, Amgens product sales increased 8%, while sales from its six key growth products rose 27%. These products now account for more than 70% of total product sales. Repatha sales grew 37% to $1.1 billion, while UPLIZNA sales increased 191% to $451 million.
Read More:GoGoMeds Appoints Harish Panchal as Chief Executive Officer
The company's operating margin also improved to 35.8%, compared with 26.4% a year earlier. Amgen shares are currently trading at 26.8 times trailing earnings, higher than the S&P 500's 21.9 times.
Amgen (AMGN) shares gained 43.5% between May 15 and November 13, 2026, compared with a 2.6% rise in the S&P 500. During this period, the company announced several positive developments for its key growth medicines. These included new trial results on August 31 showing that Repatha, it's cholesterol drug, reduced the risk of death in high-risk adults who had not previously suffered a heart attack or stroke.
However, in the six months before May 15, Amgen shares had fallen by around 1%. This raises the question of whether these positive developments could have been predicted while the stock price was still relatively flat.
Amgen shares are trading at a higher valuation than the broader market. The stock has a price earnings ratio of 26.8, compared with 21.9 for the S&P 500. The company also expects operating expenses to increase significantly in the fourth quarter due to its usual year-end spending.
Amgen is expected to release it's next results in February 2027. Investors will be watching sales growth across the company's six key growth medicines.
Amgen develops and produces medicines to treat some of the world's most serious diseases. By combining science and technology, the company provides treatments to millions of patients and works to help them live healthier, and longer lives.









